Results Schedules, Management Changes, and Pending NDA Approvals - Research Report on Questcor, VIVUS, Exelixis, Incyte, and Chelsea Therapeutics

NEW YORK, July 25, 2013 /PRNewswire/ --

Today, Investors' Reports announced new research reports highlighting Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), VIVUS, Inc. (NASDAQ: VVUS), Exelixis, Inc. (NASDAQ: EXEL), Incyte Corporation (NASDAQ: INCY), and Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Questcor Pharmaceuticals, Inc. Research Report

On July 12, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced that it will release its Q2 2013 financial results on July 30, 2013, after the close of the US financial markets. On the same day, the Company will host a conference call and slide presentation via webcast at 4:30 p.m. ET / 1:30 p.m. PT, to discuss results and highlights of Q2 2013, as well as current corporate developments. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/QCOR]

VIVUS, Inc. Research Report

On July 22, 2013, VIVUS, Inc. (VIVUS) announced that its Board of Directors has appointed Michael Astrue to the position of Chairman, and Anthony Zook to the position of CEO of the Company, with immediate effect. VIVUS also informed that prior to joining the Company, Astrue served as the CEO of Transkaryotic Therapies, Chairman of the Massachusetts Biotechnology Council, and Commissioner of Social Security; while Zook was the Executive Vice President of Global Commercial Operations at AstraZeneca and President of Medimmune. The Full Research Report on VIVUS, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/VVUS]

Exelixis, Inc. Research Report

On July 18, 2013, Exelixis, Inc. (Exelixis) announced that it will release its Q2 2013 financial results on August 6, 2013, after the market close. The release will be followed by a live webcast at 5:00 p.m. EDT / 2:00 p.m. PDT on the same day. During the webcast, the Company's management team will discuss the financial results of Exelixis, as well as financial outlook and development program, and plans for cabozantinib. The Company will also provide a general business update. The Full Research Report on Exelixis, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/EXEL]

Incyte Corporation Research Report

On July 11, 2013, Incyte Corporation (Incyte) announced that it will host its Q2 2013 conference call on August 1, 2013 at 8:30 a.m. ET to discuss financial results. The press release for the results will be issued on the same day at 7:00 a.m. ET. In Q1 2013, the Company reported total revenues of $71.1 million as compared to $36.2 million in Q1 2012. According to Incyte, the growth in Q1 2013 revenue was due to increased Jakafi product revenue and $5.9 million of Jakavi product royalties from Novartis. The Full Research Report on Incyte Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/INCY]

Chelsea Therapeutics International, Ltd. Research Report

On July 17, 2013, Chelsea Therapeutics International, Ltd. (Chelsea Therapeutics) announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the New Drug Application (NDA) resubmission seeking approval to market NORTHERA (droxidopa), an orally active synthetic precursor of norepinephrine, for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in patients with primary autonomic failure, dopamine beta hydroxylase deficiency, and non-diabetic autonomic neuropathy. The Company said that the FDA has deemed the resubmission as a complete response to its March 28, 2012 Complete Response Letter and assigned a new Prescription Drug User Fee Act (PDUFA) goal date of January 3, 2014. The Full Research Report on Chelsea Therapeutics International, Ltd. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.investorsreports.com/report/2013-07-23/CHTP]

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

http://www.InvestorsReports.com

SOURCE Investors' Reports